For example, FT819 (NCT06308978), an iPSC-based allogeneic CAR-T cell therapy, is designed to target CD19 for the depletion of pathogenic B cells in SLE patients and is currently in a Phase I clinical trial. The gene discussed is CD19; the disease is systemic lupus erythematosus.